Literature DB >> 29938520

Introduction of a Mobile Adverse Event Reporting System Is Associated With Participation in Adverse Event Reporting.

Daniel S Rubin1, Colin Pesyna2, Sharon Jakubczyk1, Chuanhong Liao1, Avery Tung1.   

Abstract

Physicians underutilize adverse event reporting systems. Web-based platforms have increased participation; thus, it was hypothesized that a mobile application would increase adverse event reporting. The authors developed a mobile reporting application for iOS and Android operating systems and performed a retrospective review on reporting rates by clinicians in the Department of Anesthesia and Critical Care. Monthly reporting rates were calculated for the intervention year and for the 2 prior years (2013-2016). The Wilcoxon rank sum test and χ2 test were used to evaluate significance. Overall monthly reporting rates for all clinicians were 15.3 ± 7 for the first time period, 17.3 ± 6 for the second time period, and 27.9 ± 7 for the third time period ( P = .0035). The majority of reports in the third time period were submitted using the mobile application (193/337, 57%, P = .026). Deployment of a mobile application reduced barriers to adverse event reporting and increased monthly reporting rates for all clinicians.

Keywords:  adverse event reporting; anesthesia; mobile application; patient safety

Mesh:

Year:  2018        PMID: 29938520     DOI: 10.1177/1062860618781920

Source DB:  PubMed          Journal:  Am J Med Qual        ISSN: 1062-8606            Impact factor:   1.852


  2 in total

1.  A Novel Approach to Establish and Enhance Event Reporting Systems Among Resident Physicians.

Authors:  Saud Siddiqui; Johnnatan Marin; Genevieve Kupsky; Theodore Quan; Sarah E Frasure; Neal Sikka; Ali Pourmand
Journal:  AEM Educ Train       Date:  2020-11-22

2.  An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.

Authors:  Josiah Tatenda Masuka; Star Khoza
Journal:  Pharmacol Res Perspect       Date:  2020-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.